Pediatric Oncology Clinical Trials
| All Studies | |
|---|---|
| AALL1521 INCB 18424-269 | A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia |
| AALL1631 | International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones |
| AALL1731 temp close 12/19/2022 | A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome BLymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl |
| AALL1732 |
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk BALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
| Lymphoma | |
| ANHL1931 |
A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma |
| All Relapse | |
| AALL1621 |
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) |
| AALL1821 Groups 1, 2 & 3 Temporary Closure |
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse |
| APAL2020SC |
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias |
| AML | |
| AAML1831 |
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations |
| AAML18P1 |
Stopping Tyrosine Kinase Inhibitors (TKI) to AssessTreatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP) |
| Neuroblastoma | |
| ANBL00B1 |
Children's Oncology Group Neuroblastoma Biology Studies |
| ANBL1531 |
A Phase 3 Study of 131I-Metaiodobenzlguanidine (131I-MIBG) or Crizotinib Added To Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) |
| ANBL1232 Group B open Groups A2 and C Temporary Closure |
Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study. |
| ANBL1821 Temporary closure |
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma |
| ANBL19P1 Temporary closure 06/27/2022 |
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma |
| CNS | |
| ACNS1422 |
A Phase 2 Study of Reduced Therapy for Newly Diagnosed AverageRisk WNT-Driven Medulloblastoma Patients |
| ACNS1723 |
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355) |
| ACNS1831 |
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma |
| ACNS1833 |
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) |
| ACNS1931 Stratum 1 Closed |
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination with Vinblastine for Non-NF1, Non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
| ACNS2031 |
A Phase 3 Study of Sodium Thiosulfate for Reduction of CisplatinInduced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features |
| Renal / Germ Cell | |
| AREN03B2 |
Renal Tumors Classification, Biology, and Banking Study |
| AGCT1531 AVA Hears Temporary Closure 0212/2021 |
A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
| AGCT1532 |
Phase 3 Accelerated BEP Trial: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors |
| AREN1921 | Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) |
| Osteosarcoma | |
| AOST2031 |
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma |
| Liver | |
| AHEP1531 Temporary Closure of Accrual to Group D, effective June 30, 2023 |
AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) |
| Hodgkin's | |
| AHOD2131 |
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma |
| S1826 temp closure 10/5/2022 |
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma |
| Soft Tissue Sarcoma | |
| ARST2031 |
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINOCPO Maintenance |
| ARST2032 |
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma |
| Solid Tumor Relapse | |
| APEC1621-Master | APEC1621-Master NCI-COG Pediatric Match (Molecular Analysis For Therapy Choice) Master VersionControl Protocol |
| Hematology Protocols | |
| CSEG101B2201 |
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with VasoOcclusive Crisis |
| Other Studies | |
| ACCL20N1CD |
Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States |
| ACCL21C2 |
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer |
| ALTE07C1 |
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer: A Groupwide Non-Therapeutic Study |
| DCP-001 |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Research Program (NCORP) |
| ALTE2031 |
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors |
| APEC14B1 |
The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study |